Abstract:Background About 90% of mortality associated with cancer is attributable to metastatic disease. Thus, our ability to treat cancer is largely dependent on the capacity to prevent metastasis. Metabolic reprogramming is recognized to support cellular transformation and tumor initiation; however, whether or how metabolism supports metastasis remains an open question. This study seeks to identify metabolic predictors of metastasis, with the rationale that understanding metabolic changes will lead to novel insights into metastasis and perhaps new therapies to treat metastatic disease. Materials and methods A patient-derived xenograft model was used in which metastasis in mice strongly correlates with metastatic history of patient donors. Tumor cells were originally obtained from melanoma patients and passaged exclusively in highly immunocompromised mice [1]. In this study, 17 of such tumor lines were investigated including 6 lines with low metastatic potential, 9 high metastatic potential and 2 intermediate metastatic potential. Tumor cells were implanted subcutaneously into mice, yielding 62 tumors. 3-4 biopsies from each primary tumor were harvested, for a total of 185 samples. A mass spectrometry (MS)-based analytical platform was used to characterize >150 metabolites in each specimen. The relative abundance of metabolites that contribute most to the distinction of highly metastatic from inefficiently metastatic melanomas was examined using statistical tools. Results Unsupervised hierarchical clustering revealed that in every case, a given tumor biopsy was most closely related to all other biopsies descended from the same parental tumor. In addition, as a frequent mutation in melanoma, BRAFmutant tumors were easily distinguished from BRAF-wild type tumors by their metabolomic signatures. More importantly, several metabolic pathways were found altered significantly when metabolomics profiles between melanoma lines with high or low metastatic potentials were compared. Conclusions The MS-based metabolomic analysis of patient-derived melanoma xenografts demonstrates that tumors contain individual metabolomic identities that can be tracked. It may be possible to identify metabolomic features from primary tumors that predict various aspects of tumor biology, including the propensity to metastasize. The altered metabolic pathways in highly metastatic melanomas are potential therapeutic targets.

The Abundance of Metabolites Related to Protein Methylation Correlates with the Metastatic Capacity of Human Melanoma Xenografts

Multimodal Metabolic Imaging Reveals Pigment Reduction and Lipid Accumulation in Metastatic Melanoma

FADS2-mediated fatty acid desaturation and cholesterol esterification are signatures of metabolic reprogramming during melanoma progression

Identifying Metabolomic Features That Predict Metastasis of Melanoma from a Primary Site

Effects of RNA Methylation N6-methyladenosine Regulators on Malignant Progression and Prognosis of Melanoma.

Metabolic Mechanisms Regulating Distinct Steps of the Melanoma Metastatic Cascade

Metabolic heterogeneity confers differences in melanoma metastatic potential

Melanoblast transcriptome analysis reveals pathways promoting melanoma metastasis

Abstract 5541: The unique metabolite landscape of the aged microenvironment dictates melanoma migratory and invasive capacity

Melanoblast transcriptome analysis reveals novel pathways promoting melanoma metastasis

Metabolic Profiling Reveals a Dependency of Human Metastatic Breast Cancer on Mitochondrial Serine and One-Carbon Unit Metabolism

Metabolism heterogeneity in melanoma fuels deactivation of immunotherapy: Predict before protect

Molecular characterization of metastatic progression in patient derived xenograft models of malignant uveal melanoma

Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis

Targeting glutamate metabolism in melanoma

Functional Annotation of Metastasis-associated MicroRNAs of Melanoma

MET receptor serves as a promising target in melanoma brain metastases

High expression of DNA repair pathways is associated with metastasis in melanoma patients

Mitochondrial Metabolism in Melanoma

Identifying metabolic reprogramming phenotypes with glycolysis-lipid metabolism discoordination and intercellular communication for lung adenocarcinoma metastasis

Network-Based Identification of Altered Stem Cell Pluripotency and Calcium Signaling Pathways in Metastatic Melanoma